Results on Merck & Co (NYSE: MRK) and Ridgeback Biotherapeutics’ molnupiravir massively impacted not just the share price of the US pharma giant and its competitors on Friday, but could also have a significant effect on the COVID-19 pandemic itself.
Merck’s shares closed nearly 10% higher on Friday after the announcement of interim Phase III results, which showed that the investigational antiviral pill significantly reduced the risk of hospitalization or death in at risk, non-hospitalized adult patients with mild-to-moderate COVID-19.
"Antiviral treatments that can be taken at home to keep people with COVID-19 out of the hospital are critically needed"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze